BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260528
DTEND;VALUE=DATE:20260603
DTSTAMP:20260514T021346
CREATED:20260311T084731Z
LAST-MODIFIED:20260311T084731Z
UID:10011-1779926400-1780444799@thebiocalendar.com
SUMMARY:BIO Partnering for Oncology
DESCRIPTION:Connect with innovators\, investors\, and companies advancing cancer breakthroughs\, in person or virtually\, during Chicago’s biggest oncology event through the BIO Partnering™ system.
URL:https://thebiocalendar.com/event/bio-partnering-for-oncology/
LOCATION:Chicago\, Chicago\, IL\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260529T110000
DTEND;TZID=America/Los_Angeles:20260529T120000
DTSTAMP:20260514T021346
CREATED:20260429T155001Z
LAST-MODIFIED:20260429T155001Z
UID:10304-1780052400-1780056000@thebiocalendar.com
SUMMARY:CAR-T Strategy in 2026: Scaling Autologous\, Advancing Allogeneic
DESCRIPTION:Join this thought leadership panel exploring how the CAR-T landscape continues to evolve as clinical and commercial experience grows. As autologous therapies expand into additional settings and allogeneic approaches continue to be studied\, organizations are reassessing where to focus research\, development\, and operational efforts. \nThis discussion brings together perspectives from across the cell therapy ecosystem to examine key scientific\, operational\, and market considerations shaping CAR-T development in 2026 and beyond. \nWhat you will learn:\n    ~ Differences in the current use and development of autologous and allogeneic CAR-T therapies\n    ~ Factors influencing manufacturing\, supply chain\, and clinical approaches\n    ~ Regulatory\, commercial\, and operational considerations\n    ~ Areas of ongoing development and uncertainty \nKey topics include:\n    ~ Modality strategy: roles of autologous vs allogeneic approaches\n    ~ Manufacturing: scalability\, consistency\, and process control\n    ~ Clinical development: expansion and durability considerations\n    ~ Access: reimbursement and site-of-care factors\n    ~ Regulatory & CMC: expectations and comparability\n    ~ Supply chain: patient-specific vs off-the-shelf models\n    ~ Collaboration: cross-sector partnership approaches \nThis panel provides perspectives on how organizations are approaching CAR-T strategy\, including near-term priorities and longer-term considerations.
URL:https://thebiocalendar.com/event/car-t-strategy-in-2026-scaling-autologous-advancing-allogeneic/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-29-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
END:VCALENDAR